CN101636149A - 用于重新构成的粉末 - Google Patents
用于重新构成的粉末 Download PDFInfo
- Publication number
- CN101636149A CN101636149A CN200880008342A CN200880008342A CN101636149A CN 101636149 A CN101636149 A CN 101636149A CN 200880008342 A CN200880008342 A CN 200880008342A CN 200880008342 A CN200880008342 A CN 200880008342A CN 101636149 A CN101636149 A CN 101636149A
- Authority
- CN
- China
- Prior art keywords
- tmc278
- water
- soluble polymer
- powder
- vinylacetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Abstract
Description
给药日 | 总剂量(mg(eq.)) | 处理 | 组别 | 状况 |
第0天(2006年7月24日) | 5050 | A1)B2) | 12 | 禁食,给药后立即喂食禁食,给药后立即喂食 |
第14天(2006年8月07日) | 5050 | C3)C3) | 12 | 禁食,给药后立即喂食禁食,给药后立即喂食 |
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07104082.8 | 2007-03-14 | ||
EP07104082 | 2007-03-14 | ||
PCT/EP2008/053056 WO2008110619A1 (en) | 2007-03-14 | 2008-03-14 | Powders for reconstitution |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101636149A true CN101636149A (zh) | 2010-01-27 |
CN101636149B CN101636149B (zh) | 2014-08-06 |
Family
ID=38055251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880008342.0A Active CN101636149B (zh) | 2007-03-14 | 2008-03-14 | 用于重新构成的粉末 |
Country Status (18)
Country | Link |
---|---|
US (1) | US8916558B2 (zh) |
EP (1) | EP2043608B1 (zh) |
JP (1) | JP5554571B2 (zh) |
KR (1) | KR101580297B1 (zh) |
CN (1) | CN101636149B (zh) |
AP (1) | AP2964A (zh) |
AR (2) | AR065720A1 (zh) |
AU (1) | AU2008225774B2 (zh) |
BR (1) | BRPI0808897B8 (zh) |
CA (1) | CA2676981C (zh) |
CL (1) | CL2008000746A1 (zh) |
ES (1) | ES2535162T3 (zh) |
IL (1) | IL199874A (zh) |
MX (1) | MX2009009743A (zh) |
RU (1) | RU2477133C2 (zh) |
TW (1) | TWI494133B (zh) |
WO (1) | WO2008110619A1 (zh) |
ZA (1) | ZA200906344B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104684545A (zh) * | 2012-09-27 | 2015-06-03 | 巴斯夫欧洲公司 | 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂 |
CN113440529A (zh) * | 2020-03-25 | 2021-09-28 | 江苏恒瑞医药股份有限公司 | 一种可注射的药物组合物及其制备方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
CL2008000746A1 (es) | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
PL2696848T3 (pl) | 2011-04-15 | 2020-12-28 | Janssen Pharmaceutica N.V. | Liofilizowane nanozawiesiny leków |
CN114126655A (zh) * | 2019-07-03 | 2022-03-01 | 爱尔兰詹森科学公司 | 用利匹韦林治疗儿科患者的hiv的方法 |
CN114392241B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种利匹韦林片及其制备方法 |
WO2023203257A1 (en) * | 2022-04-22 | 2023-10-26 | Janssen Sciences Ireland Unlimited Company | Freeze dried compositions |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3089818A (en) * | 1960-06-02 | 1963-05-14 | Baxter Laboratories Inc | Water dispersible antibiotics |
US5182111A (en) | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US5368864A (en) * | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
DK0489181T3 (da) * | 1990-07-19 | 1996-11-18 | Otsuka Pharma Co Ltd | Fast præparat |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
CA2121129A1 (en) | 1991-10-29 | 1993-05-13 | Patrick Soon-Shiong | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
AU4079593A (en) | 1992-05-13 | 1993-12-13 | Wellcome Foundation Limited, The | Therapeutic combinations |
JPH06316524A (ja) | 1992-09-11 | 1994-11-15 | Naoyuki Inoue | 抗エイズウイルス剤 |
TW401303B (en) | 1994-07-01 | 2000-08-11 | Janssen Pharmaceutica Nv | Anti-HIV triple combination |
US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
KR100801588B1 (ko) | 1999-09-21 | 2008-02-05 | 스키에파마 캐나다 인코포레이티드 | 생물학적 유효 물질의 표면 변형된 미립자 조성물 |
ES2258018T3 (es) | 1999-09-24 | 2006-08-16 | Janssen Pharmaceutica N.V. | Dispersiones solidas antivirales. |
US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
TW200800298A (en) | 2000-01-27 | 2008-01-01 | Zentaris Ag | Compressed microparticles for dry injection |
US7135465B2 (en) | 2000-03-30 | 2006-11-14 | Bristol-Myers Squibb Company | Sustained release beadlets containing stavudine |
US20040115268A1 (en) | 2000-04-26 | 2004-06-17 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
DE10050199A1 (de) | 2000-10-11 | 2002-04-25 | Ethicon Gmbh | Flächiges Implantat mit im Ultraschall detektierbaren Elementen |
CA2431319A1 (en) * | 2000-12-11 | 2002-06-20 | Hiroto Bando | Pharmaceutical composition having an improved water solubility |
ES2333645T3 (es) * | 2001-06-22 | 2010-02-25 | Bend Research, Inc. | Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros. |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US20030166509A1 (en) | 2001-11-20 | 2003-09-04 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery and methods of use thereof |
CN100554245C (zh) | 2002-08-09 | 2009-10-28 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
AU2003278766A1 (en) | 2002-09-04 | 2004-03-29 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
AU2003291457A1 (en) | 2002-11-08 | 2004-06-03 | Glaxo Group Limited | Pharmaceutical antiviral compositions |
AP1927A (en) | 2002-11-15 | 2008-12-10 | Tibotec Pharm Ltd | Substituted indolepyridinium as anti-infective compounds |
WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
JP5602333B2 (ja) | 2003-02-07 | 2014-10-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Hiv感染の予防のためのピリミジン誘導体 |
KR100629771B1 (ko) | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
RU2373923C2 (ru) * | 2004-06-08 | 2009-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтические композиции |
MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
AU2005279158C1 (en) | 2004-09-02 | 2010-12-16 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile |
PT1632232E (pt) | 2004-09-02 | 2011-08-02 | Janssen Pharmaceutica Nv | Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo |
EP2623095A1 (en) | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Hiv-感染之預防 |
AR056652A1 (es) * | 2005-04-11 | 2007-10-17 | Tibotec Pharm Ltd | Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento |
WO2006110889A2 (en) | 2005-04-11 | 2006-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Multi-layer structure having a predetermined layer pattern including an agent |
US20090142401A1 (en) | 2005-06-07 | 2009-06-04 | Leah Elizabeth Appel | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release |
JP5243247B2 (ja) * | 2005-07-28 | 2013-07-24 | アイエスピー インヴェストメンツ インコーポレイテッド | スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品 |
AP2936A (en) | 2006-01-20 | 2014-07-31 | Tibotec Pharm Ltd | Long term treatment of HIV-infection with TMC278 |
BRPI0712346B8 (pt) | 2006-06-06 | 2021-05-25 | Janssen R & D Ireland | processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica |
PL2040671T3 (pl) | 2006-06-23 | 2018-08-31 | Janssen Sciences Ireland Uc | Wodne zawiesiny TMC278 |
WO2008060360A2 (en) | 2006-09-28 | 2008-05-22 | Surmodics, Inc. | Implantable medical device with apertures for delivery of bioactive agents |
CL2008000746A1 (es) | 2007-03-14 | 2008-09-22 | Tibotec Pharm Ltd | Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida. |
AU2008274185B2 (en) | 2007-07-12 | 2014-07-03 | Janssen Sciences Ireland Uc | Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile |
WO2009046299A2 (en) | 2007-10-04 | 2009-04-09 | Boston Scientific Scimed, Inc | Implantable drug depot for intrathecal drug delivery system for pain management |
WO2010047819A1 (en) | 2008-10-24 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Hydroxyethylamino sulfonamide derivatives |
-
2008
- 2008-03-13 CL CL200800746A patent/CL2008000746A1/es unknown
- 2008-03-13 TW TW097108780A patent/TWI494133B/zh active
- 2008-03-13 AR ARP080101032A patent/AR065720A1/es not_active Application Discontinuation
- 2008-03-14 MX MX2009009743A patent/MX2009009743A/es active IP Right Grant
- 2008-03-14 JP JP2009553156A patent/JP5554571B2/ja active Active
- 2008-03-14 US US12/530,665 patent/US8916558B2/en active Active
- 2008-03-14 AU AU2008225774A patent/AU2008225774B2/en active Active
- 2008-03-14 ES ES08717800.0T patent/ES2535162T3/es active Active
- 2008-03-14 RU RU2009137911/15A patent/RU2477133C2/ru active
- 2008-03-14 AP AP2009004969A patent/AP2964A/xx active
- 2008-03-14 BR BRPI0808897A patent/BRPI0808897B8/pt active IP Right Grant
- 2008-03-14 CA CA2676981A patent/CA2676981C/en active Active
- 2008-03-14 WO PCT/EP2008/053056 patent/WO2008110619A1/en active Application Filing
- 2008-03-14 EP EP08717800.0A patent/EP2043608B1/en active Active
- 2008-03-14 KR KR1020097017592A patent/KR101580297B1/ko active IP Right Grant
- 2008-03-14 CN CN200880008342.0A patent/CN101636149B/zh active Active
-
2009
- 2009-07-15 IL IL199874A patent/IL199874A/en active IP Right Grant
- 2009-09-11 ZA ZA2009/06344A patent/ZA200906344B/en unknown
-
2019
- 2019-01-21 AR ARP190100128A patent/AR114086A2/es not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104684545A (zh) * | 2012-09-27 | 2015-06-03 | 巴斯夫欧洲公司 | 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂 |
CN104684545B (zh) * | 2012-09-27 | 2018-04-03 | 巴斯夫欧洲公司 | 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂 |
CN113440529A (zh) * | 2020-03-25 | 2021-09-28 | 江苏恒瑞医药股份有限公司 | 一种可注射的药物组合物及其制备方法 |
CN113440529B (zh) * | 2020-03-25 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 一种可注射的药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0808897A2 (pt) | 2014-09-02 |
EP2043608A1 (en) | 2009-04-08 |
JP5554571B2 (ja) | 2014-07-23 |
TWI494133B (zh) | 2015-08-01 |
US8916558B2 (en) | 2014-12-23 |
AR114086A2 (es) | 2020-07-22 |
AU2008225774A1 (en) | 2008-09-18 |
RU2477133C2 (ru) | 2013-03-10 |
US20100120795A1 (en) | 2010-05-13 |
AP2964A (en) | 2014-09-30 |
JP2010520918A (ja) | 2010-06-17 |
KR20090119964A (ko) | 2009-11-23 |
MX2009009743A (es) | 2009-09-23 |
CL2008000746A1 (es) | 2008-09-22 |
TW200911303A (en) | 2009-03-16 |
AU2008225774B2 (en) | 2014-04-10 |
CN101636149B (zh) | 2014-08-06 |
EP2043608B1 (en) | 2015-01-21 |
CA2676981A1 (en) | 2008-09-18 |
BRPI0808897B1 (pt) | 2020-10-20 |
IL199874A (en) | 2016-02-29 |
ZA200906344B (en) | 2015-04-29 |
BRPI0808897B8 (pt) | 2021-05-25 |
KR101580297B1 (ko) | 2015-12-24 |
ES2535162T3 (es) | 2015-05-05 |
WO2008110619A1 (en) | 2008-09-18 |
AR065720A1 (es) | 2009-06-24 |
IL199874A0 (en) | 2010-04-15 |
CA2676981C (en) | 2015-01-13 |
RU2009137911A (ru) | 2011-04-20 |
AP2009004969A0 (en) | 2009-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101636149B (zh) | 用于重新构成的粉末 | |
JP5288791B2 (ja) | 難水溶性物質含有微細化組成物 | |
ES2688278T3 (es) | Forma de dosificación farmacéutica que comprende uno o más ingredientes activos antirretrovirales | |
AU2013358897A1 (en) | Pharmaceutical compositions | |
CA2866133A1 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
EP3197430A1 (en) | Long acting pharmaceutical compositions | |
JP5464584B2 (ja) | 抗hiv化合物の臭化水素酸塩 | |
WO2006073154A1 (ja) | 医薬組成物及びその製造方法 | |
WO2007086689A1 (en) | A solid dispersion comprising ubidecarenone, a process for preparing the same and a pharmaceutical composition comprising the same | |
US20110082161A1 (en) | Powders for reconstitution | |
CN105939715A (zh) | 抗病毒化合物的固定剂量组合 | |
EP3244895B1 (en) | Novel pharmaceutical composition | |
WO2020226889A1 (en) | Formulations of uridine triacetate in triacetin | |
TW201240660A (en) | Pharmaceutical composition for treating HCV infections | |
TW200526664A (en) | Phosphodiesterase V inhibitor formulation | |
US20160375017A1 (en) | Solid Pharmaceutical Compositions for Treating HCV | |
KR20070025070A (ko) | 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: IRELAND JANSSEN R + D COMPANY Free format text: FORMER OWNER: JANSSEN R + D IRELAND Effective date: 20150724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: JANSSEN R + D IRELAND Free format text: FORMER NAME: TIBOTEC PHARM LTD. Owner name: TIBOTEC PHARM LTD. Free format text: FORMER NAME: TIBOTEC NV |
|
CP01 | Change in the name or title of a patent holder |
Address after: The Irish Village Patentee after: JANSSEN R&D IRELAND Address before: The Irish Village Patentee before: TIBOTEC PHARMACEUTICALS Address after: The Irish Village Patentee after: TIBOTEC PHARMACEUTICALS Address before: The Irish Village Patentee before: TIBOTEC PHARMACEUTICALS Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150724 Address after: The Irish Village Patentee after: JANSSEN R&D IRELAND Address before: The Irish Village Patentee before: JANSSEN R&D IRELAND |